H.C. Wainwright sees increased uncertainty for Sarepta franchise
H.C. Wainwright sees increased uncertainty for Sarepta’s Elevidys franchise after the European Medicines Agency placed a clinical hold on three drug trials. The clinical hold on ...
I-Mab price target lowered to $7 from $8 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on I-Mab (IMAB) to $7 from $8 and keeps a Buy rating on the shares. The company continues to ...
HC Wainwright Predicts Daré Bioscience FY2029 Earnings
Equities researchers at HC Wainwright issued their FY2029 earnings estimates for shares of Daré Bioscience in a research note ...
HC Wainwright Estimates CG Oncology FY2029 Earnings
HC Wainwright issued their FY2029 EPS estimates for CG Oncology in a note issued to investors on Monday, March 31st. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings ...